{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+A&page=19", "query": { "intervention": "Part A", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 8722, "total_pages": 873, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+A&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Part+A&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T20:52:28.463Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02840994", "title": "A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "CV301", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2016-12", "completion_date": "2020-01", "has_results": false, "last_update_posted_date": "2020-02-27", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 7, "location_summary": "Tampa, Florida • Indianapolis, Indiana • Metairie, Louisiana + 4 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02840994" }, { "nct_id": "NCT00952666", "title": "Transrectal Ultrasound Imaging of the Prostate Gland and Neurovascular Bundles During Robot-Assisted Laparoscopic Radical Prostatectomy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "TRUS-RALRP", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "MALE", "summary": "35 Years to 75 Years · Male only" }, "enrollment_count": 6, "start_date": "2008-11", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2010-09-13", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00952666" }, { "nct_id": "NCT04132557", "title": "A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Attention Deficit Disorder With Hyperactivity" ], "interventions": [ { "name": "Methylphenidate", "type": "DRUG" }, { "name": "Lisdexamfetamine", "type": "DRUG" }, { "name": "Atomoxetine", "type": "DRUG" }, { "name": "Amphetamine", "type": "DRUG" }, { "name": "Dextroamphetamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 430000, "start_date": "2019-10-09", "completion_date": "2019-10-25", "has_results": false, "last_update_posted_date": "2025-06-25", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 1, "location_summary": "Titusville, New Jersey", "locations": [ { "city": "Titusville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04132557" }, { "nct_id": "NCT00000912", "title": "A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Indinavir sulfate", "type": "DRUG" }, { "name": "Abacavir sulfate", "type": "DRUG" }, { "name": "Amprenavir", "type": "DRUG" }, { "name": "Nelfinavir mesylate", "type": "DRUG" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Levocarnitine", "type": "DRUG" }, { "name": "Adefovir dipivoxil", "type": "DRUG" }, { "name": "Saquinavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 475, "start_date": null, "completion_date": "2000-05", "has_results": false, "last_update_posted_date": "2021-10-29", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 44, "location_summary": "Los Angeles, California • Menlo Park, California • San Diego, California + 27 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Menlo Park", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000912" }, { "nct_id": "NCT06067230", "title": "A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Syncytial Virus" ], "interventions": [ { "name": "mRNA-1345", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1153, "start_date": "2023-10-06", "completion_date": "2026-07-24", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 32, "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 28 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06067230" }, { "nct_id": "NCT04462328", "title": "Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2021-04-29", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 2, "location_summary": "St Louis, Missouri • Columbus, Ohio", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04462328" }, { "nct_id": "NCT07665294", "title": "Combination CurQD and Vedolizumab in Ulcerative Colitis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "CurQD", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Vedolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ryan C Ungaro", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 160, "start_date": "2026-10-01", "completion_date": "2027-06-23", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 3, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07665294" }, { "nct_id": "NCT07066722", "title": "A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4524184", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifabutin", "type": "DRUG" }, { "name": "Phenytoin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 126, "start_date": "2025-07-07", "completion_date": "2025-12-17", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 2, "location_summary": "Lenexa, Kansas • Salt Lake City, Utah", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07066722" }, { "nct_id": "NCT06185751", "title": "Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "WS-CART-CS1", "type": "BIOLOGICAL" }, { "name": "Lymphodepleting chemotherapy", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-08-22", "completion_date": "2040-08-31", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06185751" }, { "nct_id": "NCT02082977", "title": "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Neoplasms" ], "interventions": [ { "name": "GSK2816126", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2014-04-24", "completion_date": "2017-06-20", "has_results": true, "last_update_posted_date": "2020-02-25", "last_synced_at": "2026-10-20T20:52:28.463Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02082977" } ] }